Cited by 373Diabetes Management and ResearchDiabetes and associated disordersDiabetes Management and Education

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

A Randomized, Prospective Trial Comparing the Efficacy of Continuous Subcutaneous Insulin Infusion With Multiple Daily Injections Using Insulin Glargine

Open access

Doyle (Boland), Elizabeth A., Weinzimer, Stuart A., Steffen, Amy T., Ahern, Jo Ann H., Vincent, Miranda, Tamborlane, William V.·2004·Diabetes Care

DOI 10.2337/diacare.27.7.1554

Open this paper in CoChat — free account Open PDF

Abstract

OBJECTIVE—The efficacy of the insulin analogs now available for multiple daily injection (MDI) and continuous subcutaneous insulin infusion (CSII) therapy in type 1 diabetes has not yet been established in pediatric patients. Our principal aim in this short-term study was to compare the efficacy of CSII to MDI with glargine in lowering HbA1c levels in children and adolescents with type 1 diabetes. RESEARCH DESIGN AND METHODS—Thirty-two youth with type 1 diabetes (age 8–21 years) were randomly assigned to receive either MDI treatment with once-daily glargine and premeal/snack insulin aspart or CSII with insulin aspart. Dose titration in both groups was based on home self-monitored blood glucose measurements and monthly HbA1c. HbA1c, total daily insulin dose (TDD), self-monitored blood glucose readings, and adverse events were compared after 16 weeks of therapy. RESULTS—While there was no significant change in the glargine group (HbA1c 8.2% at baseline vs. 8.1% at 16 weeks), youth randomized to CSII had a sharp reduction in HbA1c levels, from 8.1 to 7.2% after 16 weeks of therapy (P < 0.02 vs. baseline and <0.05 vs. glargine group). TDD was unchanged in the glargine group, but significantly dropped with CSII (1.4 units/kg at baseline vs. 0.9 units/kg at 16 weeks, P < 0.01). Both groups had similar basal doses and insulin-to-carbohydrate ratios. Fasting self-monitored blood glucose was similar in both groups, but lunch, dinner, and bedtime readings were significantly lower in the CSII group (P < 0.01). CONCLUSIONS—Lower HbA1c and premeal glucose levels were more achievable in this short-term study with CSII than with glargine-based MDI treatment. CSII is an efficacious treatment to improve metabolic control in youth with type 1 diabetes.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.2337/diacare.27.7.1554

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Effect of intensive diabetes treatment on the development and progression of long-term complications in adolescents with insulin-dependent diabetes mellitus: Diabetes Control and Complications Trial
(1994) · The Journal of Pediatrics · doi:10.1016/s0022-3476(94)70190-3 · Cited by 1,654
Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro.
Lepore, M., Pampanelli, S., Fanelli, C., Porcellati, F., Bartocci, L., Di Vincenzo, A., Cordoni, C., Costa, E., Brunetti, P., & Bolli, G. B. (2000) · Diabetes · doi:10.2337/diabetes.49.12.2142 · Cited by 818
Standards of Medical Care for Patients With Diabetes Mellitus
American Diabetes Association (2003) · Diabetes Care · doi:10.2337/diacare.26.2007.s33 · Cited by 614
Continuous subcutaneous insulin infusion. A new way to lower risk of severe hypoglycemia, improve metabolic control, and enhance coping in adolescents with type 1 diabetes.
Boland, E. A., Grey, M. J., Oesterle, A., Fredrickson, L. P., & Tamborlane, W. V. (1999) · Diabetes Care · doi:10.2337/diacare.22.11.1779 · Cited by 430
Self-citation
A Modified Quality-of-Life Measure for Youths: Psychometric Properties
Ingersoll, G. M., & Marrero, D. G. (1991) · The Science of Diabetes Self-Management and Care · doi:10.1177/014572179101700219 · Cited by 325
Comparison of Continuous Subcutaneous Insulin Infusion and Multiple Daily Injection Regimens in Children With Type 1 Diabetes: A Randomized Open Crossover Trial
Weintrob, N., Benzaquen, H., Galatzer, A., Shalitin, S., Lazar, L., Fayman, G., Lilos, P., Dickerman, Z., & Phillip, M. (2003) · PEDIATRICS · doi:10.1542/peds.112.3.559 · Cited by 236
Safety and effectiveness of insulin pump therapy in children and adolescents with type 1 diabetes
Plotnick, L. P., Clark, L. M., Brancati, F. L., & Erlinger, T. (2003) · Diabetes Care · doi:10.2337/diacare.26.4.1142 · Cited by 216
Outcome measures for clinical trials in cystic fibrosis Summary of a Cystic Fibrosis Foundation Consensus Conference
Ramsey, B. W., & Boat, T. F. (1994) · The Journal of Pediatrics · doi:10.1016/s0022-3476(94)70301-9 · Cited by 200
Insulin pump therapy in pediatrics: a therapeutic alternative to safely lower HbA1c levels across all age groups
Ahern, J. A., Boland, E. A., Doane, R., Ahern, J. J., Rose, P., Vincent, M., & Tamborlane, W. V. (2002) · Pediatric Diabetes · doi:10.1034/j.1399-5448.2002.30103.x · Cited by 174
Self-citation

Show all 15 references

Sorted by citations

Items 101–200 of 373

Does treatment with an insulin pump improve glycaemic control in children and adolescents with type 1 diabetes? A retrospective case-control study: CSII and MDI in children and adolescents
Brorsson, A. L., Viklund, G., Örtqvist, E., & Lindholm Olinder, A. (2015) · Pediatric Diabetes · doi:10.1111/pedi.12209 · Cited by 52
Continuous Glucose Monitoring in Insulin-Treated Patients in Non-ICU Settings
Gómez, A. M., & Umpierrez, G. E. (2014) · Journal of Diabetes Science and Technology · doi:10.1177/1932296814546025 · Cited by 52
Light Control of Protein Solubility Through Isoelectric Point Modulation
Nadendla, K., & Friedman, S. H. (2017) · Journal of the American Chemical Society · doi:10.1021/jacs.7b08465 · Cited by 51
Insulin Delivery Systems: Reducing Barriers to Insulin Therapy and Advancing Diabetes Mellitus Treatment
Brunton, S. (2008) · The American Journal of Medicine · doi:10.1016/j.amjmed.2008.03.025 · Cited by 49
Efficacy of Continuous Subcutaneous Insulin Infusion in Type 2 Diabetes Mellitus: A Survey on a Cohort of 102 Patients with Prolonged Follow-Up
Reznik, Y., Morera, J., Rod, A., Coffin, C., Rousseau, E., Lireux, B., & Joubert, M. (2010) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2010.0110 · Cited by 48
Past, present, and future of insulin pump therapy: better shot at diabetes control
Sherr, J. L., & Tamborlane, W. V. (2008) · Mount Sinai Journal of Medicine A Journal of Translational and Personalized Medicine · doi:10.1002/msj.20055 · Cited by 46
Self-citation
A Cost-Effectiveness Analysis of Continuous Subcutaneous Insulin Injection versus Multiple Daily Injections in Type 1 Diabetes Patients: A Third-Party US Payer Perspective
Charles, M. S., Lynch, P. M., Graham, C., & Minshall, M. E. (2008) · Value in Health · doi:10.1111/j.1524-4733.2008.00478.x · Cited by 46
Insulin Aspart in the Management of Diabetes Mellitus: 15 Years of Clinical Experience
Hermansen, K., Bohl, M., & Schioldan, A. G. (2015) · Drugs · doi:10.1007/s40265-015-0500-0 · Cited by 47
“As shown in Table 5, insulin aspart CSII has shown comparable safety to MDI therapy [98, 112, 113, 116, 117].”
BackgroundMethod
Classification of Distinct Baseline Insulin Infusion Patterns in Children and Adolescents With Type 1 Diabetes on Continuous Subcutaneous Insulin Infusion Therapy
Holterhus, P., Odendahl, R., Oesingmann, S., Lepler, R., Wagner, V., Hiort, O., Holl, R. W., & the German/Austrian DPV Initiative and the German Pediatric CSII Working Group (2007) · Diabetes Care · doi:10.2337/dc06-2105 · Cited by 45
Reduction of Glycosylated Hemoglobin Following 6 Months of Continuous Subcutaneous Insulin Infusion in an Indian Population with Type 2 Diabetes
Kesavadev, J., Balakrishnan, S., Ahammed, S., & Jothydev, S. (2009) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2008.0128 · Cited by 44
“5,11,12 Our study, however, had an entirely different patient population (Asian Indians) from previous work in this area and achieved similar clinical improvement.”
Facilitating technology adoption in the NHS: negotiating the organisational and policy context – a qualitative study
Llewellyn, S., Procter, R., Harvey, G., Maniatopoulos, G., & Boyd, A. (2014) · Health Services and Delivery Research · doi:10.3310/hsdr02230 · Cited by 43
Insulin Aspart
Reynolds, N. A., & Wagstaff, A. J. (2004) · Drugs · doi:10.2165/00003495-200464170-00013 · Cited by 43
Comparison of pharmacokinetic properties, physicochemical stability, and pump compatibility of 3 rapid-acting insulin analogues— aspart, lispro, and glulisine
Bode, B. W. (2011) · Endocrine Practice · doi:10.4158/ep10260.ra · Cited by 56
Which factors predict glycemic control in children diagnosed with type 1 diabetes before 6.5 years of age?
Shalitin, S., & Phillip, M. (2011) · Acta Diabetologica · doi:10.1007/s00592-011-0321-x · Cited by 42
“Published randomized comparisons of MDI and CSII have reported controversial results in terms of metabolic control in children [24–26].”
Result
Continuous Subcutaneous Insulin Infusion versus Multiple Daily Injections of Insulin
Cohen, N. D., Minshall, M. E., Sharon-Nash, L., Zakrzewska, K. E., Valentine, W. J., & Palmer, A. J. (2007) · PharmacoEconomics · doi:10.2165/00019053-200725100-00006 · Cited by 42
Feasibility and Safety of Insulin Pump Therapy in Children Aged 2 to 7 Years With Type 1 Diabetes: A Retrospective Study
Berhe, T., Postellon, D. C., Wilson, B. E., & Stone, R. (2006) · PEDIATRICS · doi:10.1542/peds.2005-2363 · Cited by 43
Therapy with insulin glargine (Lantus®) in toddlers, children and adolescents with type 1 diabetes
Colino, E. I., López-Capapé, M., Golmayo, L., Álvarez, M. A., Alonso, M., & Barrio, R. (2005) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2005.02.004 · Cited by 41
Point: Are Insulin Pumps Underutilized in Type 1 Diabetes? Yes
Pickup, J. C. (2006) · Diabetes Care · doi:10.2337/dc06-0011 · Cited by 41
“In studies comparing glargine with pump therapy, A1C or fructosamine values were improved on CSII versus glargine (23,24,32), but in relatively well-controlled subjects, A1C percentages were similar (25).”
Background
Metabolic Control in Children with Diabetes Mellitus Who are Younger than 6 Years at Diagnosis: Continuous Subcutaneous Insulin Infusion as a First Line Treatment?
Sulmont, V., Souchon, P., Gouillard-Darnaud, C., Fartura, A., Salmon-Musial, A. S., Lambrecht, E., Mauran, P., & Abély, M. (2010) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2009.12.034 · Cited by 40
ADDENBROOKE'S HOSPITAL
Cooper, C. H. (2012) · Cambridge University Press eBooks · doi:10.1017/cbo9781139175760.044 · Cited by 40
A randomized pilot study in Type 1 diabetes complicated by severe hypoglycaemia, comparing rigorous hypoglycaemia avoidance with insulin analogue therapy, CSII or education alone
Thomas, R. M., Aldibbiat, A. M., Griffin, W., Cox, M. A. A., Leech, N., & Shaw, J. (2007) · Diabetic Medicine · doi:10.1111/j.1464-5491.2007.02196.x · Cited by 40
Improvements in cognition, mood and behaviour following commencement of continuous subcutaneous insulin infusion therapy in children with type 1 diabetes mellitus: a pilot study
Knight, S., NORTHAM, E. A., Donath, S. M., Gardner, A., Harkin, N., Taplin, C. E., Joy, P., Cameron, F. J., & Ambler, G. R. (2008) · Diabetologia · doi:10.1007/s00125-008-1197-3 · Cited by 40
Estimating treatment effect via simple cross design synthesis
Kaizar, E. E. (2011) · Statistics in Medicine · doi:10.1002/sim.4339 · Cited by 39
Key elements for successful intensive insulin pump therapy in individuals with type 1 diabetes
Cukierman‐Yaffe, T., Konvalina, N., & Cohen, O. (2011) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2011.01.002 · Cited by 39
Clarifying responsibility for self‐management of diabetes in adolescents using insulin pumps – a qualitative study
Olinder, A. L., Nyhlin, K. T., & Smide, B. (2011) · Journal of Advanced Nursing · doi:10.1111/j.1365-2648.2010.05588.x · Cited by 44
Closed-loop insulin delivery – what lies between where we are and where we are going?
Steil, G. M., & Rebrin, K. (2005) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2.2.353 · Cited by 39
“At present, multiple daily insulin injection therapy remains common, continuous subcutaneous insulin infusion shows benefit in reducing haemoglobin A1c in some [12,13], but not all, [14] studies, and continuous glucose monitoring data are only available retrospectively [15].”
Background
Insulin Micropump with Embedded Pressure Sensors for Failure Detection and Delivery of Accurate Monitoring
Dumont-Fillon, D., Tahriou, H., Conan, C., & Chappel, E. (2014) · Micromachines · doi:10.3390/mi5041161 · Cited by 38
Early Pharmacokinetic and Pharmacodynamic Effects of Mixing Lispro With Glargine Insulin
Cengiz, E., Tamborlane, W. V., Martin-Fredericksen, M., Dziura, J., & WEINZIMER, S. A. (2010) · Diabetes Care · doi:10.2337/dc09-2118 · Cited by 38
“Poor compliance with the requirements of frequent injections is a major contributing cause of failure to achieve target plasma glucose and A1C levels in adolescents with type 1 diabetes using multiple daily injection regimes (6).”
BackgroundSelf-citation
Continuous Subcutaneous Insulin Infusion and Multiple Dose of Insulin Regimen Display Similar Patterns of Blood Glucose Excursions in Pediatric Type 1 Diabetes
Alemzadeh, R., Palma-Sisto, P., Parton, E. A., & Holzum, M. K. (2005) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2005.7.587 · Cited by 36
Continuous subcutaneous insulin infusion versus multiple daily injections in children and young people at diagnosis of type 1 diabetes: the SCIPI RCT
Blair, J., McKay, A., Ridyard, C. H., Thornborough, K., Bedson, E., Peak, M., Didi, M., Annan, F., Gregory, J. W., Hughes, D. A., et al. (2018) · Health Technology Assessment · doi:10.3310/hta22420 · Cited by 39
Age-Specific Advantages of Continuous Subcutaneous Insulin Infusion as Compared With Multiple Daily Injections in Pediatric Patients
Kordonouri, O., Hartmann, R., Lauterborn, R., Barnekow, C., Hoeffe, J., & Deiss, D. (2006) · Diabetes Care · doi:10.2337/diacare.29.01.06.dc05-1740 · Cited by 37
Insulin Pump Therapy from the Time of Diagnosis of Type 1 Diabetes
Ramchandani, N., Ten, S., Anhalt, H., SINHA, S. K., Ching, J., Finkelstein, A., & Maclaren, N. K. (2006) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2006.8.663 · Cited by 37
“Doyle et al. 9 found that pediatric patients on CSII had significantly better metabolic control compared with those on a basal/bolus insulin regimen using a combination of rapid-acting insulin aspart and long-acting glargine insulin.”
Association of CTLA-4 (+49A/G) Gene Polymorphism with Type 1 Diabetes Mellitus in Egyptian Children
Mosaad, Y. M., Elsharkawy, A. A., & Eldeek, B. S. (2011) · Immunological Investigations · doi:10.3109/08820139.2011.579215 · Cited by 37
“(Doyle et al., 2004; Nimri et al., 2006).”
Treatment satisfaction and glycemic control in young Type 1 diabetic patients in transition from pediatric health care: CSII versus MDI
Maiorino, M. I., Bellastella, G., Petrizzo, M., Improta, M. R., Brancario, C., Castaldo, F., Olita, L., Giugliano, D., & Esposito, K. (2013) · Endocrine · doi:10.1007/s12020-013-0060-6 · Cited by 38
The Use of Insulin Pump Therapy in the Pediatric Age Group
Shalitin, S., & Phillip, M. (2008) · Hormone Research in Paediatrics · doi:10.1159/000129673 · Cited by 36
Technology Utilization in Black Adolescents with Type 1 Diabetes: Exploring the Decision-Making Process
Mencher, S., WEINZIMER, S. A., Nally, L. M., Name, M. A. V., Nuñez-Smith, M., & Sadler, L. S. (2022) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0413 · Cited by 37
Self-citation
The Use of Continuous Subcutaneous Insulin Infusion (CSII): Parental and Professional Perceptions of Self-care Mastery and Autonomy in Children and Adolescents
Weissberg-Benchell, J. A., Goodman, S. S., Antisdel, J. E., & Zebracki, K. (2007) · Journal of Pediatric Psychology · doi:10.1093/jpepsy/jsm050 · Cited by 35
“To our knowledge, only one study reported the demographic characteristics of pediatric CSII users (Doyle et al., 2004), which were comparable with our current sample.”
Result
The Integrated MiniMed Paradigm Real-Time Insulin Pump and Glucose Monitoring System: Implications for Improved Patient Outcomes
Mastrototaro, J. J., & Lee, S. (2009) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2008.0134 · Cited by 36
An observational study comparing continuous subcutaneous insulin infusion (CSII) and insulin glargine in children with type 1 diabetes
Schiaffini, R., Ciampalini, P., Spera, S., Cappa, M., & Crinò, A. (2004) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.520 · Cited by 34
“trials in youth with type 1 diabetes [22,23,32] reach the conclusion that both CSII and glargine improve glycaemic control, reduce the blood glucose variability and decrease the frequency of severe hypoglycaemic events, with the CSII probably being the more efficacious approach in terms of reduction of hypoglycaemia […”
Background
New technologies for diabetes: a review of the present and the future
Ramchandani, N., & Heptulla, R. A. (2012) · International Journal of Pediatric Endocrinology · doi:10.1186/1687-9856-2012-28 · Cited by 39
“better quality of life in patients who use insulin pumps compared to those on multiple daily injections (MDI) [58-79].”
Background
Piezoelectric Silicon Micropump for Drug Delivery Applications
Bußmann, A. B., Leistner, H., Zhou, D., Wackerle, M., Congar, Y., Richter, M., & Hubbuch, J. J. (2021) · Applied Sciences · doi:10.3390/app11178008 · Cited by 34
The Impact of Racial and Ethnic Health Disparities in Diabetes Management on Clinical Outcomes: A Reinforcement Learning Analysis of Health Inequity Among Youth and Young Adults in the SEARCH for Diabetes in Youth Study
Kahkoska, A. R., Pokaprakarn, T., Alexander, G. R., Crume, T., Dabelea, D., Divers, J., Dolan, L. M., Jensen, E. T., Lawrence, J. M., Marcovina, S. M., et al. (2021) · Diabetes Care · doi:10.2337/dc21-0496 · Cited by 34
Insulin Therapy in Pediatric Patients with Type I Diabetes: Continuous Subcutaneous Insulin Infusion versus Multiple Daily Injections
Nahata, L. (2006) · Clinical Pediatrics · doi:10.1177/0009922806290565 · Cited by 32
“Study 3: Doyle et al (2004)10 A randomized trial comparing CSII to MDIs was performed in patients at the Yale Children’s Diabetes Clinic, with the following criteria: ages 8 to 21 years, with no other health problem except treatment for thyroid or celiac disease, treatment with insulin for at least…”
Method
Improving glycaemic control in children and adolescents: which aspects of therapy really matter?
Skinner, T. C., & Cameron, F. J. (2009) · Diabetic Medicine · doi:10.1111/j.1464-5491.2009.02895.x · Cited by 31
Insulin-pump use in everyday practice: Data from an exhaustive regional registry in France
Riveline, J., Jollois, F.-X., Messaoudi, N., Franc, S., Lagarde, F., Lormeau, B., Charitanski, D., Benoit, A., Pichard, S., Deburge, A., et al. (2008) · Diabetes & Metabolism · doi:10.1016/j.diabet.2007.10.010 · Cited by 32
Basal insulin and total daily insulin dose in children with type 1 diabetes using insulin pumps
Pańkowska, E., Szypowska, A., & Lipka, M. (2008) · Pediatric Diabetes · doi:10.1111/j.1399-5448.2008.00375.x · Cited by 31
Insulin Doses before and One Year after Pump Start: Children Have a Reversed Dawn Phenomenon
Nicolajsen, T., Samuelsson, A., & Hanås, R. (2012) · Journal of Diabetes Science and Technology · doi:10.1177/193229681200600314 · Cited by 31
The addition of rosiglitazone to insulin in adolescents with type 1 diabetes and poor glycaemic control: a randomized-controlled trial
Stone, M., Walker, J. L., Chisholm, D. J., Craig, M. E., Donaghue, K. C., Crock, P., Anderson, D., & Verge, C. F. (2008) · Pediatric Diabetes · doi:10.1111/j.1399-5448.2008.00383.x · Cited by 29
Multiple Daily Injections OR Insulin Pump Therapy: Choosing the Best Option for Your Patient—An Evidence-based Approach
Joshi, M., & Choudhary, P. (2015) · Current Diabetes Reports · doi:10.1007/s11892-015-0644-z · Cited by 29
Comparison of Optimised MDI versus Pumps with or without Sensors in Severe Hypoglycaemia (the Hypo COMPaSS trial)
Little, S. A., Chadwick, T. J., Choudhary, P., Brennand, C., Stickland, J., Barendse, S., Olateju, T., Leelarathna, L., Walkinshaw, E., Tan, H. K., et al. (2012) · BMC Endocrine Disorders · doi:10.1186/1472-6823-12-33 · Cited by 30
“There have been relatively few trials to date with glargine as the basal insulin in the MDI comparator group [30,31].”
Background
Basal insulin supplementation in Type 1 diabetic children: A long-term comparative observational study between continuous subcutaneous insulin infusion and glargine insulin
Schiaffini, R., Patera, P. I., Bizzarri, C., Ciampalini, P., & Cappa, M. (2007) · Journal of Endocrinological Investigation · doi:10.1007/bf03346351 · Cited by 27
An Update on the Long‐Acting Insulin Analogue Glargine
Horsdal, H. T., Johnsen, S. P., & Rungby, J. (2006) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/j.1742-7843.2006.pto_352.x · Cited by 27
Glycated Hemoglobin Differences Among Blog-Reading Adults With Type 1 Diabetes Compared With Those Who Do Not Read Blogs: Cross-Sectional Study
Oser, S. M., Stuckey, H. L., Parascando, J. A., McGinley, E. L., Berg, A. S., & Oser, T. K. (2019) · JMIR Diabetes · doi:10.2196/13634 · Cited by 27
“As CGMs have evolved for patient use, earlier mixed results [13,14,15] have shifted to show benefits [16,17], especially when using CGM to augment insulin pump therapy [18-21].”
Background
The renaissance of insulin pump treatment in childhood type 1 diabetes
Tamborlane, W. V., Swan, K. L., Sikes, K. A., Steffen, A. T., & WEINZIMER, S. A. (2006) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-006-9018-9 · Cited by 27
“In contrast, patients randomized to CSII were able to significantly lower HbA1c values compared to their own baseline levels and versus the glargine group at 16 weeks [34].”
ResultSelf-citation
The rise of technology in diabetes care. Not all that is new is necessarily better
Acerini, C. L. (2016) · Pediatric Diabetes · doi:10.1111/pedi.12366 · Cited by 26
Risk and benefits of continuous subcutaneous insulin infusion (CSII) treatment in school children and adolescents
Battelino, T. (2006) · Pediatric Diabetes · doi:10.1111/j.1399-543x.2006.00167.x · Cited by 26
A longitudinal observational study of insulin therapy and glycaemic control in Scottish children with Type 1 diabetes: DIABAUD 3
Scottish Study Group for the Care of the Young with Diabetes (2006) · Diabetic Medicine · doi:10.1111/j.1464-5491.2006.01962.x · Cited by 25
Continuous subcutaneous insulin infusion (CSII) in children with type 1 diabetes
Tamborlane, W. V., Sikes, K. A., Steffen, A. T., & WEINZIMER, S. A. (2006) · Diabetes Research and Clinical Practice · doi:10.1016/s0168-8227(06)70011-0 · Cited by 24
Self-citation
Efficacy and Safety of Continuous Subcutaneous Insulin Infusion vs. Multiple Daily Injections on Type 1 Diabetes Children Aged ≤ 18 Years Old, a Meta-Analysis with Randomized Control Trials
Qin, Y. H., Yang, L.-H., Huang, X.-L., Chen, X.-H., & Yao, H. (2018) · Journal of Clinical Research in Pediatric Endocrinology · doi:10.4274/jcrpe.0053 · Cited by 23
HLA-DQB1* alleles and genetic susceptibility to type 1 diabetes mellitus
Mosaad, Y. M. (2012) · World Journal of Diabetes · doi:10.4239/wjd.v3.i8.149 · Cited by 25
Impact of Treatments on Diabetic Control and Gastrointestinal Symptoms After Total Pancreatectomy
Struyvenberg, M. R., Fong, Z. V., Martin, C. R., Tseng, J. F., Clancy, T. E., Castillo, C. F. F.-D., Tillman, H., Bellin, M. D., & Freedman, S. D. (2017) · Pancreas · doi:10.1097/mpa.0000000000000917 · Cited by 23
Flexibility of rapid-acting insulin analogues in children and adolescents with diabetes mellitus
Danne, T. (2007) · Clinical Therapeutics · doi:10.1016/j.clinthera.2007.12.014 · Cited by 23
Are Glucose Readings Sufficient to Adjust Insulin Dosage?
Bashan, E., Herman, W. H., & Hodish, I. (2010) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2010.0112 · Cited by 22
“…the original study 90% of patients incurred minor hypoglycemia, and the frequency of severe hypoglycemia was 0.16 events per person-year) and was comparable to that reported in subjects treated with intensive insulin therapy (most available data derive from patients with type 1 diabetes 19–21 ).”
Influential
Diabetes Technology During the Past 30 Years: A Lot of Changes and Mostly for the Better
Deeb, L. C. (2008) · Diabetes Spectrum · doi:10.2337/diaspect.21.2.78 · Cited by 22
Changes in insulin therapy regimens over 10 yr in children and adolescents with type 1 diabetes attending diabetes camps
Redon, I., Beltrand, J., Martin, D., Taupin, P., Choleau, C., Morandini, M., Cahané, M., Robert, J., & teams, O. B. O. T. A. H. C. (2013) · Pediatric Diabetes · doi:10.1111/pedi.12062 · Cited by 21
“Controlled studies have shown lower HbA1c with intensive treatment regimens, compared to more conventional treatment (9–11), while comparisons between multiple injections (MDI) and CSII have shown improvement in metabolic control with CSII over glargine (12) or concluded that there was not enough data to give a conclu…”
Background
Long-Term Metabolic Effects of Continuous Subcutaneous Insulin Infusion Therapy in Type 1 Diabetes
Cohen, N. D., Hong, E. S., Drie, C. V., Balkau, B., & Shaw, J. E. (2013) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2012.0331 · Cited by 21
Insulin pump therapy in youth with type 1 diabetes: toward closed-loop systems
Tauschmann, M., & Hovorka, R. (2014) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2014.910192 · Cited by 22
“Some noncontrolled cohort studies [19] and randomized clinical trials (RCTs) [24] reported a decrease in HbA1c with insulin pump therapy compared to MDI [19,24], whereas others did not [25].”
Background
Impact of insulin pumps on glycaemic control in a pump‐naïve paediatric regional population
de Bock, M. I., Gunn, A. J., Holt, J., Derraik, J. G. B., Reed, P., Cutfield, W. S., Mouat, F., Hofman, P. L., & Jefferies, C. (2011) · Journal of Paediatrics and Child Health · doi:10.1111/j.1440-1754.2011.02245.x · Cited by 21
Insulin Pump Use in Adults with Type 1 Diabetes—Practical Issues
Shetty, G. K., & Wolpert, H. A. (2010) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2010.0002 · Cited by 21
Observational Studies in a Learning Health System
Institute of Medicine (2013) · National Academies Press eBooks · doi:10.17226/18438 · Cited by 21
Clinical value of Flash glucose monitoring in patients with type 1 diabetes treated with continuous subcutaneous insulin infusion
Moreno-Fernández, J., Pazos-Couselo, M., González‐Rodríguez, M., Rozas, P., Delgado‐Rodríguez, M., Aguirre, M., & López, J. M. G. (2018) · Endocrinología Diabetes y Nutrición · doi:10.1016/j.endinu.2018.04.003 · Cited by 22
Insulin Analogues in Children and Teens with Type 1 Diabetes: Advantages and Caveats
Rachmiel, M., Perlman, K., & Daneman, D. (2005) · Pediatric Clinics of North America · doi:10.1016/j.pcl.2005.07.010 · Cited by 20
A evolução da insulinoterapia no diabetes melito tipo 1
Pires, A. C., & Chacra, A. R. (2008) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302008000200014 · Cited by 21
External insulin pump treatment in the day-to-day management of diabetes: benefits and future prospectives
Hanaire, H. P. (2011) · Diabetes & Metabolism · doi:10.1016/s1262-3636(11)70964-8 · Cited by 20
A Comparative Pulse Accuracy Study of Two Commercially Available Patch Insulin Infusion Pumps
Bowen, J. L., & Allender, C. J. (2016) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2016.12.02.79 · Cited by 20
Sustained metabolic control and low rates of severe hypoglycaemic episodes in preschool diabetic children treated with continuous subcutaneous insulin infusion
Pańkowska, E., Szypowska, A., Lipka, M., & Skórka, A. (2007) · Acta Paediatrica · doi:10.1111/j.1651-2227.2007.00301.x · Cited by 20
“Other investigators have demonstrated no change in BMI during pump treatment (25,17).”
Background
Diabetes mellitus type 1 in adults
Dedov, I. I., Shestakova, M. V., Mayorov, A. Y., Шамхалова, М. Ш., Nikonova, T. V., Sukhareva, O. Y., Пекарева, Е. В., Ibragimova, L. I., Mikhina, M. S., Galstyan, G. R., et al. (2020) · Diabetes Mellitus · doi:10.14341/dm12505 · Cited by 19
A Comparison of Continuous Subcutaneous Insulin Infusion vs. Multiple Daily Insulin Injection in Children with Type I Diabetes in Kuwait: Glycemic Control, Insulin Requirement, and BMI
Abdul-Rasoul, M. M., Mousa, M., Al-Mahdi, M., Al-Sanae, H., Al‐Abdulrazzaq, D., & Alkandari, H. (2015) · Oman Medical Journal · doi:10.5001/omj.2015.69 · Cited by 18
Continuous Glucose Monitors and Activity Trackers to Inform Insulin Dosing in Type 1 Diabetes: The University of Virginia Contribution
Fabris, C., Özaslan, B., & Breton, M. D. (2019) · Sensors · doi:10.3390/s19245386 · Cited by 19
The effect of socioeconomic deprivation on efficacy of continuous subcutaneous insulin infusion: a retrospective paediatric case-controlled survey
on behalf of the North West England Paediatric Diabetes Network, Senniappan, S., Hine, P., Tang, W., Campbell, J., Bone, M., Sankar, V., Robinson, M., Smith, C. P., Cooper, C., et al. (2011) · European Journal of Pediatrics · doi:10.1007/s00431-011-1482-x · Cited by 18
The effort required to achieve and maintain optimal glycemic control
Rosenthal, E. S., Bashan, E., Herman, W. H., & Hodish, I. (2011) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2011.01.002 · Cited by 18
Multiple daily injections in young patients using the ezy-BICC bolus insulin calculation card, compared to mixed insulin and CSII
Anderson, D. G. (2008) · Pediatric Diabetes · doi:10.1111/j.1399-5448.2008.00484.x · Cited by 18
Insulin Pump Treatment of Childhood Type 1 Diabetes
WEINZIMER, S. A., Sikes, K. A., Steffen, A. T., & Tamborlane, W. V. (2005) · Pediatric Clinics of North America · doi:10.1016/j.pcl.2005.07.004 · Cited by 17
Self-citation
Flexible, intensive insulin therapy and dietary freedom in adolescents and young adults with Type 1 diabetes: a prospective implementation study
Sämann, A., Lehmann, T., Kloos, C., Braun, A., Hunger-Dathe, W., Wolf, G., & Müller, U. (2008) · Diabetic Medicine · doi:10.1111/j.1464-5491.2008.02406.x · Cited by 17
Intensive insulin therapy today: ‘basal-bolus’ using multiple daily injections or CSII?
Renard, É. (2005) · Diabetes & Metabolism · doi:10.1016/s1262-3636(05)88266-7 · Cited by 17
Pediatric Pumps
Owen, S. (2006) · The Science of Diabetes Self-Management and Care · doi:10.1177/0145721705285641 · Cited by 17
“Fasting selfmonitored blood glucose levels were similar in both groups, while lunch, dinner, and bedtime levels were significantly lower in the CSII group.(3) The same concept of switching to CSII therapy was evaluated in young children (younger than 4 years) and Susan Owen, RN, CDE”
Background
Ethnic differences in glycemic control and diabetic ketoacidosis rate among children with diabetes mellitus type 1 in the Negev area.
Hilmi, A., Pasternak, Y., Friger, M., Loewenthal, N., Haim, A., & Hershkovitz, E. (2013) · PubMed · Cited by 16
Long-term Efficacy of Insulin Pump Therapy in Children with Type 1 Diabetes Mellitus
Batajoo, R. J., Messina, C. R., & Wilson, T. A. (2012) · Journal of Clinical Research in Pediatric Endocrinology · doi:10.4274/jcrpe.751 · Cited by 16
Cochrane review: Continuous subcutaneous insulin infusion (CSII) versus multiple insulin injections for type 1 diabetes mellitus
Misso, M. L., Egberts, K. J., Page, M. J., O’Connor, D. A., & Shaw, J. E. (2010) · Evidence-Based Child Health A Cochrane Review Journal · doi:10.1002/ebch.623 · Cited by 18
Factors Correlating With Improved A1C in Children Using Continuous Subcutaneous Insulin Infusion
MCVEAN, J. J. F., Eickhoff, J. C., & MacDonald, M. J. (2007) · Diabetes Care · doi:10.2337/dc07-0614 · Cited by 16
Unchanged incidence of microalbuminuria in children with type 1 diabetes since 1986: a UK based inception cohort
Amin, R., Widmer, B., Dalton, R. N., & Dunger, D. B. (2009) · Archives of Disease in Childhood · doi:10.1136/adc.2008.144337 · Cited by 16
“…are other reports of improved glycaemic control in children using insulin pump therapy, 21 22 only a single randomised controlled trial exists, 23 which was underpowered and found at the end of follow-up (only 12 months) that no difference existed in glycaemic control between those using…”
Background
Continuous Subcutaneous Insulin Infusion in Adult Type 1 Diabetes Mellitus Patients: Results from a Public Health System
Moreno-Fernández, J., Gómez, F. J., Pinés, P. J., González, J., López, J., López, L. M., Blanco, B., Roa, C., Herránz, S., & Muñoz‐Rodríguez, J. R. (2019) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2019.0097 · Cited by 15
Contemporary Australian outcomes in childhood and adolescent type 1 diabetes: 10 years post the Diabetes Control and Complications Trial
Ambler, G. R., Fairchild, J. M., Craig, M. E., & Cameron, F. J. (2006) · Journal of Paediatrics and Child Health · doi:10.1111/j.1440-1754.2006.00889.x · Cited by 15
Evaluating Older Patients with Diabetes for Insulin Pump Therapy
Stephens, E. A., & Heffner, J. E. (2010) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2010.0024 · Cited by 15
Comparison between a multiple daily insulin injection regimen (basal once-daily glargine plus mealtime lispro) and continuous subcutaneous insulin infusion (lispro) using continuous glucose monitoring in metabolically optimized type 1 diabetes patients: A randomized open-labelled parallel study
Ruiz-de-Adana, M. S., Dominguez-Lopez, M.-E., González-Molero, I., Machado, A., Martin, V., Cardona, I., de la Higuera, M., Tapia, M. J., Soriguer, F., Ortiz, M. T. A., et al. (2015) · Medicina Clínica · doi:10.1016/j.medcli.2015.09.020 · Cited by 15
A comparison of glycaemic variability in CSII vs. MDI treated type 1 diabetic patients using CGMS
Simon, B. F., Treat, V., Marco, C. C., Rosenberg, D., Joseph, J. I., Hipszer, B. R., Li, Y., Chervoneva, I., Padron-Massara, L., & Jabbour, S. A. (2008) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2008.01932.x · Cited by 15
Efficacy of Insulin Pump Therapy on Diabetes Treatment Satisfaction and Glycemic Control Among Patients with Type 1 Diabetes Mellitus in Saudi Arabia: A Prospective Study
Hayek, A. A., Robert, A. A., Dawish, M. A. A., Braham, R. B., Goudeh, H. S., & Sabaan, F. S. A. (2015) · Diabetes Therapy · doi:10.1007/s13300-015-0107-1 · Cited by 14
“in many other studies [20, 22, 23].”
Technology and intensive management in youth with type 1 diabetes: State of the art
Wood, J., & Laffel, L. M. (2007) · Current Diabetes Reports · doi:10.1007/s11892-007-0019-1 · Cited by 14
Diabetes mellitus
Sperling, M. A., Tamborlane, W. V., Battelino, T., WEINZIMER, S. A., & Phillip, M. (2014) · Elsevier eBooks · doi:10.1016/b978-1-4557-4858-7.00028-7 · Cited by 16
Self-citation
Sexual activity in diabetic patients treated by continuous subcutaneous insulin infusion therapy
Riveline, J. P., Franc, S., Biedzinski, M., Jollois, F.-X., Messaoudi, N., Lagarde, F., Lormeau, B., Pichard, S., Varroud-Vial, M., Deburge, A., et al. (2010) · Diabetes & Metabolism · doi:10.1016/j.diabet.2010.01.004 · Cited by 13

Authors: Doyle (Boland), E. A., Weinzimer, S. A., Steffen, A. T., Ahern, J. A. H., Vincent, M., & Tamborlane, W. V.
Affiliations: From the Department of Pediatrics and the Children’s Clinical Research Center, Yale University School of Medicine, New Haven, Connecticut
Yale University (US)
ORCID: Weinzimer, Stuart A.
Tamborlane, William V.
Venue: Diabetes Care
Publisher: American Diabetes Association
Published: 2004-07-01
Volume: 27
Issue: 7
Pages: 1554-1558
ISSN: 0149-5992 (ISSN-L)
1935-5548
DOI: 10.2337/diacare.27.7.1554
OpenAlex: W2138976255
Cited by: 373
References: 15
Citations by year: 2026: 3 · 2025: 2 · 2024: 6 · 2023: 2 · 2022: 9 · 2021: 8 · 2020: 10 · 2019: 13 · 2018: 14 · 2017: 9 · 2016: 15 · 2015: 19 · 2014: 24 · 2013: 20 · 2012: 23
FWCI: 17.43
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: Diabetes Care (publishedVersion)
PubMed (publishedVersion)
Funders: Yale University
Novo Nordisk
National Institutes of Health (5u01hd037251-05)
National Center for Research Resources (RR06022)
Eunice Kennedy Shriver National Institute of Child Health and Human Development (HD 37251)
Topics: Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
Keywords: type 1 diabetes, insulin pump therapy, multiple daily insulin injections, insulin glargine, insulin aspart, glycemic control, HbA1c, total daily insulin dose, self-monitoring of blood glucose, pediatric diabetes, adolescents
MeSH terms: Insulin Glargine, Adolescent, Adult, Child, Diabetes Mellitus, Type 1, Drug Administration Schedule, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Injections, Subcutaneous, Insulin, Insulin Infusion Systems, Blood Glucose Self-Monitoring, Patient Selection, Postprandial Period, Insulin, Long-Acting

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

A Randomized, Prospective Trial Comparing the Efficacy of Continuous Subcutaneous Insulin Infusion With Multiple Daily Injections Using Insulin Glargine

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks